A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors

Trial Profile

A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Tremelimumab (Primary) ; Durvalumab
  • Indications Adenocarcinoma; Bladder cancer; Breast cancer; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jun 2018 Planned End Date changed from 5 Oct 2018 to 24 Dec 2018.
    • 19 Jun 2018 Planned primary completion date changed from 20 Mar 2018 to 24 Dec 2018.
    • 20 Jan 2018 Results (n= 20; As of April 5, 2017) in patients with metastatic pancreatic ductal adenocarcinoma, presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top